

Wednesday 22nd September

14:00	<i>Registration opens</i>
15:45-16:15	<i>Afternoon Tea</i>
16:15-17:15	Satellite symposium 1: Bone Markers in Cancer Supported by Roche Diagnostics
17:30-17:40	Opening Welcome Address Peter Croucher (Sheffield, UK)
17:40-18:45	Greg Mundy: A Tribute Chaired by Jack Martin (Melbourne, Australia) Speakers to include: Theresa Guise (Indianapolis, USA) Babatunde "Kay" Oyajobi (San Antonio, USA) David Roodman (Pittsburgh, USA) Julie Sterling (Nashville, USA)
18:45-20:00	<i>Welcome Reception</i> <i>Cutlers' Hall</i>

Thursday 23rd September

08:00	<i>Registration opens</i>
08:30-10:00	Symposium 1: Pre-Metastatic Niches Chairs: David Roodman/tbc
08:30	THE SEARCH FOR METASTATIC FOUNDER CELLS: MOLECULAR ANALYSIS OF DISSEMINATED TUMOUR CELLS FROM BONE MARROW OF CANCER PATIENTS Christoph Klein (Regensburg, Germany)
09:00	REACTIVATION OF EMT-INDUCING TRANSCRIPTION FACTORS AND CANCER DEVELOPMENT Alain Puisieux (Lyons, France)
09:30	Oral Communications 1 HUMAN BONE MARROW-DERIVED MESENCHYMAL STEM CELL HOMING TO ORTHOTOPIC BREAST CANCER TUMORS AND PROMOTION OF BONE METASTASIS MR Reagan ^[1] , R Goldstein ^[2] , M Rosenblatt ^[2,3] , DL Kaplan ^[1] ^[1] Biomedical Engineering, Tufts University School of Engineering, Medford, MA; ^[2] Program in Genetics, Tufts University Sackler School of Biomedical Science, Boston, MA; ^[3] Department of Physiology and Medicine, Tufts University School of Medicine, Boston, MA, USA 2 TGF- β TARGET GENE NEDD9 IDENTIFIED BY GENE PROFILING PLAYS A CRITICAL ROLE IN BREAST CANCER BONE METASTASIS K Hata, Y Morita, M Nakanishi, T Nishisyou, T Yoneda

	<p>Biochemistry, Osaka University Graduate School of Dentistry, Osaka, Japan</p> <p>3 IDENTIFICATION OF PLASMA BIOMARKERS THAT PREDICT BREAST CANCER BONE METASTASIS CL Washam^[1], SD Byrum^[1], K Leitzel^[2], A Lipton^[2], LJ Suva^[1] ^[1]Department of Orthopaedic Surgery, Center for Orthopaedic Research, University of Arkansas for Medical Sciences, Little Rock, USA; ^[2]Departments of Medicine and Microbiology, Division of Oncology, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, USA</p>
10:00-10:30	<i>Coffee and Commercial Exhibition</i>
10:30-12:00	<p>Symposium 2: Stem Cell Niches Chairs: Marco Cecchini/tbc</p>
10:30	<p>STEM CELLS CAN ORGANIZE THE METASTATIC MICROENVIRONMENT IN BONE Paolo Bianco (Rome, Italy)</p>
11:00	<p>ARTIFICIAL NICHES THAT DIRECT STEM CELL FATE Matthias Lutolf (Lausanne, Switzerland)</p>
11:30	<p>Oral Communications</p> <p>4 MULTIPHOTON IMAGING OF INDIVIDUAL MYELOMA CELLS IN CALVARIAE: ASSOCIATION OF MYELOMA DEVELOPMENT WITH SITES OF BONE TURNOVER AJ Williams^[1], MA Lawson^[1], O Alamer^[1], J Hough^[1], T Bos^[2], K Vanderkerken^[2], PI Croucher^[1] ^[1]Dept of Human Metabolism, University of Sheffield, Sheffield, UK; ^[2]Dept of Haematology and Immunology, Free University of Brussels, Brussels, Belgium</p> <p>5 TGF-β PROMOTION OF GLI2 INDUCED PTHRP EXPRESSION IS INDEPENDENT OF CANONICAL HEDGEHOG SIGNALING RW Johnson^[1,2], MP Nguyen^[3], S Padalecki^[4], B Grubbs^[4], AR Merkel^[2], B Oyajobi^[4], GR Mundy^[1,2,3], JA Sterling^[1,2] ^[1]Cancer Biology, Vanderbilt University, Nashville, USA; ^[2]Center for Bone Biology, Vanderbilt University, Nashville, USA; ^[3]Medicine, Vanderbilt University, Nashville, USA; ^[4]Health Science Center, University of Texas, San Antonio, USA</p> <p>6 DENOSUMAB DECREASES PROLIFERATION IN GIANT CELL TUMOR OF BONE (GCTB) M Roudier^[1], JY Blay^[2], S Chawla^[3], C Manivel^[4], SD Nelson^[5], D Thomas^[6], L Woody^[1], R Soriano^[1], S Jun^[7], I Jacobs^[7] ^[1]Pathology Dept, Amgen Inc., Seattle, USA; ^[2]Oncology Dept, Centre Leon Berard, Lyon, France; ^[3]Oncology, Sarcoma Oncology Center, Santa Monica, USA; ^[4]Pathology Dept, Mayo, Minneapolis, USA; ^[5]Pathology Dept, University of California, Los Angeles, USA; ^[6]Oncology dept, Peter MacCallum Cancer Center, Melbourne, Australia; ^[7]Oncology Clinical development, Amgen Inc., Thousand Oaks, USA</p>
12:00-12:30	<p>Technology Platform 1 Chair: Janet Brown</p>
	<p>MOLECULAR GENETICS AND RISK OF METASTASIS Sabine Linn (Amsterdam, Netherlands)</p>

12:30-14:00	<i>Lunch, Posters and Commercial Exhibition</i>
14:00-15:30	Symposium 3: Tumour Stem Cells Chairs: Gabri van der Pluijm/tbc
14:00	CANCER AND THE EVOLUTION OF STEM CELL FATES Peter Andrews (Sheffield, UK)
14:30	QUIESCENT STEM CELLS IN INTESTINAL HOMEOSTASIS, INFLAMMATION, AND CANCER Riccardo Fodde (Rotterdam, Netherlands)
15:00	Oral Communications 7 TARGETING TUMOUR-INITIATING CELLS WITH TRAIL BASED COMBINATION THERAPY ENSURES COMPLETE AND LASTING ERADICATION OF MULTIPLE MYELOMA TUMOURS IN VIVO S Vitovski, AD Chantry, MA Lawson, PI Croucher The Mellanby Centre for Bone Research, The Medical School, Sheffield, UK 8 BMP2/7 HETERODIMERIC PROTEINS ARE POTENT ANTAGONISTS OF TGF β -INDUCED SIGNALING, INVASIVENESS AND BONE METASTASIS VIA INHIBITION OF CANCER STEM CELLS JT Buijs, G van der Horst, C van den Hoogen, M Petersen, H Cheung, B de Rooij, RCM Pelger, G van der Pluijm Urology, Leiden University Medical Center, Leiden, The Netherlands 9 DENOSUMAB VERSUS ZOLEDRONIC ACID IN PATIENTS WITH BONE METASTASES FROM CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM A PHASE 3 RANDOMIZED TRIAL J Brown ^[1] , M Carducci ^[2] , K Fizazi ^[3] , M Smith ^[4] , R Damião ^[5] , L Karsh ^[6] , P Milecki ^[7] , H Wang ^[8] , R Dansey ^[9] , C Goessl ^[9] ^[1] Cancer Research UK Clinical Centre, St James's University Hospital, Leeds, United Kingdom; ^[2] Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, USA; ^[3] Institut Gustave Roussy, University of Paris, Villejuif, France; ^[4] Genitourinary Malignancies Program, Massachusetts General Hospital Cancer Center, Boston, USA; ^[5] Urology Service, Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil; ^[6] The Urology Center of Colorado, Denver, USA; ^[7] Department of Radiotherapy, Wielkopolskie Centrum Onkologii, Poznan, Poland; ^[8] Biostatistics, Amgen Inc., Thousand Oaks, USA; ^[9] Global Development, Amgen Inc., Thousand Oaks, USA
15:30–16:30	Symposium 4: Controversies in the Use of Bone Targeted Agents Chairs: Allan Lipton/tbc
15:30	BREAST CANCER PREVENTION Rowan Chlebowski (Los Angeles, USA)
16:00	RISK OF OSTEONECROSIS OF THE JAW AND THE USE OF BONE TARGETED THERAPIES Salvatore Ruggero (New York, USA)
16:30 – 17:00	<i>Coffee and Commercial Exhibition</i>
17:00 – 18:30	Satellite Symposium 2: Targeting RANK-Ligand Supported by Amgen

20:00 – 22:30	<i>Cultural Event</i> <i>Kelham Island Museum and Brewery</i>
Friday 24th September	
08:00	<i>Registration opens</i>
08:30 -10:00	Symposium 5: Tumour Cell Homing to Bone / Endothelial Interactions Chairs: Toshio Matsumoto/tbc
08:30	BONE MARROW ENDOTHELIAL CELLS AS ACTIVE PLAYERS IN THE PATHOBIOLOGY OF MULTIPLE MYELOMA Karin Vanderkerken (Brussels, Belgium)
09:00	CELL TRAFFICKING IN MULTIPLE MYELOMA Irene Ghobrial (Boston, USA)
09:30	Oral Communications 10 RESULTS OF THE MEDICAL RESEARCH COUNCIL (MRC) MYELOMA IX STUDY: EFFECTS OF ZOLEDRONIC ACID (ZOL) ON OVERALL SURVIVAL (OS) IN PATIENTS WITH MULTIPLE MYELOMA (MM) GJ Morgan ^[1] , FE Davies ^[1] , WM Gregory ^[2] , SE Bell ^[2] , AJ Szubert ^[2] , N Navarro Coy ^[2] , J Ashcroft ^[3] , MT Drayson ^[4] , RG Owen ^[3] , GH Jackson ^[5] , JA Child ^[2] 1Haematology, Institute of Cancer Research, Royal Marsden Hospital, London, UK; 2Haematology, Institute of Cancer Research, Royal Marsden Hospital, London, UK; 3Haematology, University of Leeds, Leeds, UK; 4Medicine, University of Leeds, Leeds, UK; 5Medicine, University of Leeds, Leeds, UK; 6Molecular Medicine, University of Leeds, Leeds, UK; 7Haematology, Mid Yorkshire Hospitals NHS Trust, Wakefield, UK; 8Medicine, University of Birmingham, Birmingham, UK; 9Haematology, St. James' University Hospital, Leeds, UK; 10Haematology, University of Newcastle, Newcastle-upon-Tyne, UK; 11Haematology, University of Leeds, Leeds, UK; 20, , , (Janet checking author statement – doesn't make sense) 11 A PHASE II, RANDOMIZED, OPEN-LABEL, PILOT STUDY TO EVALUATE THE SAFETY AND THE EFFECTS ON BONE RESORPTION OF SARACATINIB (AZD0530) IN PATIENTS WITH PROSTATE CANCER OR BREAST CANCER WITH METASTATIC BONE DISEASE M Akililu ^[1] , A Hussain ^[2] , CP Evans ^[3] , RA Hannon ^[4] , A Lipton ^[5] , M Dimairo ^[4] , J Yu ^[6] , P Zobel ^[6] , FM Torti ^[1,7] , RD Finkelman ^[6] ^[1] Department of Medicine, Wake Forest University Health Sciences, Winston-Salem, NC, USA; ^[2] Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; ^[3] Department of Urology, University of California at Davis, Sacramento, CA, USA; ^[4] Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, United Kingdom; ^[5] Division of Hematology/Oncology, Pennsylvania State University Cancer Institute, Hershey, PA, USA; ^[6] AstraZeneca, Wilmington, DE, USA; ^[7] Comprehensive Cancer Center of Wake Forest University, Wake Forest University Health Sciences, Winston-Salem, NC, USA 12 62-MONTH FOLLOW-UP OF ABCSG-12: ADJUVANT ENDOCRINE THERAPY, ALONE OR IN COMBINATION WITH ZOLEDRONIC ACID, IN PREMENOPAUSAL PATIENTS WITH ENDOCRINE-RESPONSIVE EARLY BREAST CANCER M Gnant ^[1] , B Mlineritsch ^[2] , H Stoeger ^[3] , G Luschin-Ebengreuth ^[3] , S Poestlberger ^[4] , G Steger ^[1] , R

	<p>Jakesz^[1], C Singer^[1], H Eidtmann^[5], R Greil^[2] ^[1]Departments of Surgery, Oncology, and Gynecology, Medical University of Vienna, Vienna, Austria; ^[2]Department of Internal Medicine III, Oncology and Haematology, Paracelsus Medical University Salzburg, Salzburg, Austria; ^[3]Departments of Oncology and Gynecology, Medical University of Graz, Graz, Austria; ^[4]Department of Surgery, Hospital of the Sisters of Mercy, Linz, Austria; ^[5]Department of Gynecology, University of Schleswig-Holstein, Kiel, Germany</p>
10:00-10:30	<i>Coffee and Commercial Exhibition</i>
10:30 – 12:00	<p>Symposium 6: Tumour Associated Macrophages / MISCs Chairs: Ingunn Holen/tbc</p>
10:30	<p>ROLE OF MACROPHAGES IN TUMOUR PROGRESSION AND THERAPY Claire Lewis (Sheffield, UK)</p>
11:00	<p>TARGETING CANCER INVASION AND METASTASIS Margaret Frame (Edinburgh, UK)</p>
11:30	<p>Oral Communications</p> <p>13 THE ROLE OF MACROPHAGE STIMULATING PROTEIN IN METASTASIS OF BREAST CANCER TO BONE K Kretschmann^[1], SE Waltz^[2], AL Welm^[1] ^[1]Huntsman Cancer Institute and the Department of Oncological Sciences, University of Utah, Salt Lake City, USA; ^[2]Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, USA</p> <p>14 TIMP-3 UP-REGULATION FACILITATES OSTEOCLASTOGENESIS AND SUPPRESSES DC DIFFERENTIATION FROM MONOCYTES IN THE BONE MARROW MICROENVIRONMENT IN MYELOMA M Abe^[1], M Hiasa^[2], A Nakano^[1], S Nakamura^[1], H Miki^[1], C Qu^[1], K Watanabe^[3], T Harada^[1], K Kagawa^[1], K Takeuchi^[1], S Ozaki^[4], T Matsumoto^[1] ^[1]Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, Tokushima, Japan; ^[2]Biomaterials and Bioengineering, University of Tokushima Graduate School of Oral Sciences, Tokushima, Japan; ^[3]Department of Orthodontics and Dentofacial Orthopedics, University of Tokushima Graduate School of Oral Sciences, Tokushima, Japan; ^[4]Transfusion Medicine, Tokushima University Hospital, Tokushima, Japan</p> <p>15 INCIDENCE AND OUTCOMES OF OSTEONECROSIS OF THE JAW FROM AN INTEGRATED ANALYSIS OF THREE PIVOTAL RANDOMIZED DOUBLE-BLIND, DOUBLE-DUMMY PHASE 3 TRIALS COMPARING DENOSUMAB AND ZOLEDRONIC ACID FOR TREATMENT OF BONE METASTASES IN ADVANCED CANCER PATIENTS OR MYELOMA JE Brown^[1], CH Barrios^[2], IJ DieI^[3], T Facon^[4], K Fizazi^[5], T Ibrahim^[6], F Saad^[7], F Senecal^[8], SM Stemmer^[9], A Stopeck^[10], S Takahashi^[11], C Van Poznak^[12], L Zhou^[13], P Carriere^[13], A Daniels^[13], R Dansey^[13] ^[1]Cancer Research UK Clinical Centre, Leeds, UK; ^[2]Hospital Sao Lucas da PUC-RS, Rio Grande do Sul, Brazil; ^[3]Onkologische–Schwerpunktpraxis, Mannheim, Germany; ^[4]Hôpital Claude Huriez, Lille, France; ^[5]Institut Gustave Roussy, University of Paris, Villejuif, France; ^[6]Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; ^[7]University of Montreal Hospital Center, QC, Canada; ^[8]Northwest Medical Specialties, PLLC, Tacoma, WA, USA; ^[9]Institute of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Campus, Petah-Tiqva, Israel;</p>

	<p>^[i0]University of Arizona, Arizona Cancer Center, Tucson, AZ, USA; ^[i1]The Cancer Institute Hospital of JFCR Koto-ku, Tokyo, Japan; ^[i2]University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA; ^[i3]Amgen Inc., Thousand Oaks, CA, USA</p>
12:00–12:30	<p>Technology Platform 2 Chair: Cathy Van Poznak</p>
	<p>CHALLENGES OF RESEARCH ON CIRCULATING TUMOUR CELLS IN CARCINOMA PATIENTS Sabine Riethdorf (Hamburg, Germany)</p>
12:30-14:00	<p><i>Lunch, Posters and Commercial Exhibition</i></p>
14:00–14:30	<p>Cancer and Bone Society Business Meeting</p>
14:30-15:30	<p>Symposium 7: Osteoblasts and Bone Metastasis Chair: Brendan Boyce/tbc</p>
14:30	<p>NEW BONE ANABOLIC APPROACHES TO TREATING MYELOMA BONE DISEASE David Roodman (Pittsburgh, USA)</p>
15:00	<p>Oral Communications</p> <p>16 LASER-CAPTURE MICRO-DISSECTION AND GENE ARRAY ANALYSIS TO IDENTIFY NEW MOLECULES IMPLICATED IN THE DEVELOPMENT OF MYELOMA BONE DISEASE C Buckle^[1], T Andersen^[2], J-M Delaisse^[2], K Vanderkerken^[3], C Buckle^[1] ^[1]Department of Human Metabolism, University of Sheffield, Sheffield, United Kingdom; ^[2]Department of Clinical Cell Biology, University of Southern Denmark, , Denmark; ^[3]Department of Hematology, Free University Brussels, Brussels, Belgium</p> <p>17 HALOFUGINONE REDUCES BONE METASTASES: TGF-B-DEPENDENT AND INDEPENDENT EFFECTS P Juarez^[1], K Mohammad^[1], R Mckenna^[2], H Walton^[2], M Niewolna^[1], JM Chirgwin^[1], TA Guise^[1] ^[1]Medicine, Indiana University, Indianapolis, USA; ^[2]Medicine, University of Virginia, Charlottesville, USA; ^[3]Medicine, University of Virginia, Charlottesville, USA; ^[4]Medicine, University of Virginia, Charlottesville, USA; ^[5]Medicine, Indiana University, Indianapolis, USA; ^[6]Medicine, Indiana University, Indianapolis, USA; ^[7]Medicine, Indiana University, Indianapolis, USA</p> <p>18 FIRST RANDOMIZED TRIAL COMPARING BALLOON KYPHOPLASTY (BKP) TO NON-SURGICAL MANAGEMENT AMONG CANCER PATIENTS WITH VERTEBRAL COMPRESSION FRACTURES L Bastian^[1], R Pflügmacher^[2], JR Berenson^[3], P Jarzem^[4], J Zonder^[5], JB Tillman^[6], T Ashraf^[6], FD Vrionis^[7] ^[1]Orthopedie, Unfall, Hand und Wiederherstellungschirurgie, Klinikum Leverkusen, Leverkusen, Germany; ^[2]Klinik und Poliklinik für Orthopädie und Unfallchirurgie, Universitätsklinikum Bonn, Bonn, Germany; ^[3]Myeloma and Bone cancer Research, Institute for Myeloma and Bone Cancer research , West Hollywood, California, USA; ^[4]Division of Orthopaedics, Montreal General Hospital, Montreal, Quebec, Canada; ^[5]Department of Hematology and Oncology, Karmanos Cancer Institute , Detroit, USA; ^[6]Medical Department, Medtronic Spine LCC, Sunnyvale, USA; ^[7]Neuro-oncology Division, H.Lee Moffitt Cancer and Research Institute, Tampa, California, USA</p>

15:30–16:30	Symposium 8: New Therapies for Cancer-Induced Bone Disease Chairs: Jean-Jacques Body/tbc
	PRECLINICAL PERSPECTIVE Theresa Guise (Indianapolis, USA)
	CLINICAL PERSPECTIVE Cathy Van Poznak (Michigan, USA)
16:30 – 17:00	<i>Coffee and Commercial Exhibition</i>
17:00 – 18:30	Satellite Symposium 3: Bisphosphonates and Malignancy Supported by Novartis
20:00 – 23:00	<i>Conference Dinner</i> <i>City Hall</i>
Saturday 25th September	
08:30	<i>Registration opens</i>
09:00 -10:00	Symposium 9: New Concepts in Bone Metastasis Chairs: Peter Croucher/tbc
09:00	OSTEOCLAST-DEPENDENT AND –INDEPENDENT EFFECTS OF RANKL INHIBITION ON TUMORIGENESIS AND METASTASIS Bill Dougall (Seattle, USA)
09:30	INVOLVEMENT OF ACIDIC MICROENVIRONMENT IN BONE PAIN ASSOCIATED WITH CANCER COLONIZATION Toshiyuki Yoneda (Osaka, Japan)
10:00	Oral Communications 19 PATIENTS WITH BONE METASTASES FROM SOLID TUMOURS AND POOR PROGNOSTIC FEATURES MAY GAIN SURVIVAL BENEFITS FROM ZOLEDRONIC ACID J Body ^[1] , R Cook ^[2] , L Costa ^[3] , J Brown ^[4] , E Terpos ^[5] , F Saad ^[6] , A Lipton ^[7] , R Coleman ^[8] ^[1] Medicine, University Hospital Brugmann, Brussels, Belgium; ^[2] Stats & Actuarial Science, University of Waterloo, ON, Canada; ^[3] Plastic & Reconstructive Surgery, Hospital Santa Maria, Lisbon, Portugal; ^[4] Oncology, Cancer Research UK Centre, University of Leeds, Leeds, UK; ^[5] Haematology, University of Athens School of Medicine, Athens, Greece; ^[6] Surgery Urology, Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada; ^[7] Medicine, Pennsylvania State University Milton S. Hershey Medical Center, Hershey, PA; ^[8] Oncology, University of Sheffield, Weston Park Hospital, Sheffield, UK 20 DENOSUMAB VERSUS ZOLEDRONIC ACID (ZA) FOR THE TREATMENT OF BONE METASTASES: AN INTEGRATED ANALYSIS OF RESULTS FROM 2 RANDOMIZED, DOUBLE-BLIND, PHASE 3 TRIALS A Lipton ^[1] , A Stopeck ^[2] , R von Moos ^[3] , D Henry ^[4] , G Richardson ^[5] , G Rodriguez ^[6] , H Bourgeois ^[7] , C Ke ^[8] , S Jun ^[9] , R Dansey ^[9] ^[1] Division of Hematology/Oncology, Pennsylvania State University Cancer Institute, Hershey, USA; ^[2] Arizona Cancer Center, University of Arizona, Tucson, USA; ^[3] Medizinische Onkologie, Kantonsspital Graubünden, Chur, Switzerland; ^[4] Joan Karnell Cancer Center, Pennsylvania Hospital, Philadelphia, USA; ^[5] Cabrini Academic Haematology & Oncology Service, Cabrini Hospital, Malvern, Australia; ^[6] Medical Oncology Hematology, South Texas Oncology and

	<p>Hematology, San Antonio, USA; ^[7]Clinique Victor Hugo, Centre Jean Bernard, Le Mans, France; ^[8]Biostatistics, Amgen Inc., Thousand Oaks, USA; ^[9]Global Development, Amgen Inc., Thousand Oaks, USA</p> <p>21 Late breaking abstracts</p>
10:30-11:00	<i>Coffee</i>
11:00 – 12:00	<p>Symposium 10: Towards Clinical Application Chairs: Kathy Weilbaecher/tbc</p>
11:00	<p>LESSONS TO BE LEARNED FROM OSTEOSARCOMA Dominique Heymann (Nantes, France)</p>
11:30	<p>SRC INHIBITION AS AN APPROACH TO TREATING TUMOUR-INDUCED BONE DISEASE Brendan Boyce (Rochester, USA)</p>
12:00 – 13:00	<p>Debate Chair: Rob Coleman</p>
	<p>THIS HOUSE BELIEVES THAT BISPHOSPHONATES ARE NO LONGER THE AGENTS OF CHOICE IN THE TREATMENT OF CANCER ASSOCIATED BONE DISEASES</p> <p>Speakers: Mark Clemons (Ottawa, Canada) Michael Gnant (Vienna, Austria) Allan Lipton (Hershey, USA) Eugene McCloskey (Sheffield, UK)</p> <p>Over the last 15 years, the bisphosphonates have become the standard of care for the prevention of skeletal morbidity in advanced cancer. Additionally, they have a role in preventing treatment induced bone loss and may modify the course of the disease, largely through effects on the bone microenvironment. However, skeletal complications still regularly occur, and bisphosphonate treatments are either inconvenient for patients due to the need for regular intravenous infusions, or unreliable due to problems with absorption and patient adherence. New bone targeted agents, notably denosumab, are emerging and these offer a safe, convenient and highly effective alternative to bisphosphonates.</p> <p>The relative merits of bisphosphonates and denosumab will be debated by four clinical experts in the field of bone metastases.</p>
13:00	<i>Close and Departures</i>